News - Cardio-vascular

Filter

Current filters:

Cardio-vascular

Popular Filters

26 to 50 of 528 results

New NICE guidance on cardiovascular treatments

New NICE guidance on cardiovascular treatments

18-06-2014

Thousands of people with atrial fibrillation could be saved from strokes, disability or death because…

Cardio-vascularPharmaceuticalRegulationUKWarfarin Sodium

China cardiovascular drugs market set to grow to 45 billion renminbi by 2018

China cardiovascular drugs market set to grow to 45 billion renminbi by 2018

13-06-2014

A new report titled Research on China Cardiovascular Drugs Industry 2014-2018, says that, in the next…

Cardio-vascularChinaMarkets & MarketingPharmaceutical

Statin drugs may do more harm than good, article claims

13-06-2014

Statins, already the most prescribed drugs in history, are being recommended for more and more patients…

Cardio-vascularHealthcarePharmaceutical

Orexigen stock falls after FDA extends review of obesity drug

Orexigen stock falls after FDA extends review of obesity drug

11-06-2014

Obesity-focused US biopharmaceutical company Orexigen Therapeutics says that the US Food and Drug Administration…

AnorecticsBiopharmaceuticalCardio-vascularContraveHealth Medical PharmaNB32Orexigen TherapeuticsPharmaceuticalPharmacologyRegulationUSA

Boehringer’s Pradaxa gains added indication in Europe

Boehringer’s Pradaxa gains added indication in Europe

06-06-2014

German family-owned pharma major Boehringer Ingelheim said today that its blood thinner Pradaxa (dabigatran…

Boehringer IngelheimCardio-vascularEuropePharmaceuticalPradaxaRegulation

GSK launches Phase III trial with losmapimod in acute coronary syndrome

GSK launches Phase III trial with losmapimod in acute coronary syndrome

06-06-2014

UK pharma major GlaxoSmithKline has announced the start of a pivotal Phase III study, LATITUDE-TIMI 60,…

Cardio-vascularCardiologyGlaxoSmithKlinelosmapimodPharmaceuticalResearchUK

Global anti-hypertensives market will see decline as key patents expire

Global anti-hypertensives market will see decline as key patents expire

04-06-2014

Multiple major drug patent expiries will cause the global anti-hypertensive drug market value to decline…

Cardio-vascularMarkets & MarketingPharmaceuticalResearch

Boehringer Ingelheim aims for clean slate with $650 million Pradaxa settlement, says analyst

Boehringer Ingelheim aims for clean slate with $650 million Pradaxa settlement, says analyst

02-06-2014

After facing more than 2,000 law suits in the USA, claiming Pradaxa (dabigatran) caused severe or fatal…

Boehringer IngelheimCardio-vascularFinancialLegalPharmaceutical

Boehringer Ingelheim agrees $650 million comprehensive settlement of US Pradaxa litigation

Boehringer Ingelheim agrees $650 million comprehensive settlement of US Pradaxa litigation

28-05-2014

German family-owned pharma major Boehringer Ingelheim says it has reached a comprehensive settlement…

Boehringer IngelheimCardio-vascularFinancialLegalPharmaceuticalPradaxaUSA

Daiichi Sankyo launches blood thinner Efient in Japan

27-05-2014

Daiichi Sankyo said this morning that it has launched its anti-blood clotting drug Efient (prasugrel…

Cardio-vascularDaiichi SankyoEfientJapanMarkets & MarketingPharmaceuticalRegulation

EMA/CHMP again rejects Novartis’ serelaxin for AHF

26-05-2014

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has for a second…

Cardio-vascularEuropeNovartisPharmaceuticalReasanzRegulationserelaxin

Ligand licenses five programs to Viking Therapeutics

23-05-2014

US drugmaker Ligand Pharmaceuticals has out-licensed rights to five programs to Viking Therapeutics,…

Cardio-vascularDiabetesFinancialLicensingLigand PharmaceuticalsMetabolicsPharmaceuticalViking Therapeutics

Sanford-Burnham and Daiichi Sankyo collaborate on novel cardiovascular-metabolic diseases drug targets

22-05-2014

USA-based Sanford-Burnham Medical Research Institute and Japanese drug major Daiichi Sankyo have entered…

Cardio-vascularDaiichi SankyoMetabolicsPharmaceuticalResearch

AADi in-licenses Celgene’s ABI-009

20-05-2014

US clinical-stage biopharma company AADi says it has in-licensed ABI-009 from biotech firm Celgene. Financial…

AADiABI-009BiotechnologyCardio-vascularCelgeneOncologyRespiratory and Pulmonary

Cardiome out-licenses Aggrastat in select European markets

20-05-2014

Canada-based Cardiome Pharma has signed an agreement with AOP Orphan Pharmaceuticals, headquartered in…

AggrastatAOP OrphanAustriaBrinavessCardio-vascularCardiome PharmaHungaryLicensingPharmaceutical

FDA finds favorable risk:benefit balance for Boehringer’s Pradaxa

18-05-2014

As part of its ongoing review, the US Food and Drug Administration last week released latest findings…

Boehringer IngelheimCardio-vascularPharmaceuticalPradaxaRegulationUSA

US FDA stalls approval of Novartis acute heart failure drug serelaxin, issuing a CRL

US FDA stalls approval of Novartis acute heart failure drug serelaxin, issuing a CRL

16-05-2014

The US Food and Drug Administration has issued a Complete Response Letter regarding the Biologics License…

Cardio-vascularNovartisPharmaceuticalReasanzRegulationserelaxinUSA

AstraZeneca stresses confidence in independence, highlighting strong R&D pipeline

15-05-2014

Anglo-Swedish pharma major AstraZeneca, the subject of the controversial takeover attempt by Pfizer,…

AstraZenecaCardio-vascularMergers & AcquisitionsMetabolicsOncologyPharmaceuticalResearchRespiratory and Pulmonary

Ligand signs dyslipidemia related diseases accord with AstraZeneca unit

14-05-2014

US drugmaker Ligand Pharmaceuticals has entered into a licensing agreement and research collaboration…

AstraZenecaCardio-vascularLicensingLigand PharmaceuticalsOmthera PharmaceuticalsPharmaceuticalResearch

Evolocumab combined with statin results in further reduction of cholesterol levels

Evolocumab combined with statin results in further reduction of cholesterol levels

14-05-2014

Among patients with high cholesterol receiving moderate- or high-intensity statin therapy, the addition…

AmgenBiotechnologyCardio-vascularevolocumabResearch

Another disappointment for GlaxoSmithKline with darapladib

Another disappointment for GlaxoSmithKline with darapladib

13-05-2014

UK Pharma giant GlaxoSmithKline today announced disappointing headline results from its second Phase…

Cardio-vasculardarapladibGlaxoSmithKlinePharmaceuticalResearch

Encouraging results with Gilead’s combo ranolazine and dronedarone in AFB

Encouraging results with Gilead’s combo ranolazine and dronedarone in AFB

12-05-2014

US antiviral specialist Gilead Sciences has released positive results from HARMONY, a randomized, double-blind,…

BiotechnologyCardio-vasculardronedaroneGilead SciencesRanolazineResearch

26 to 50 of 528 results

Back to top